OPK Stock Forecast: All the More Reason to Consider OPKO Health Inc. (OPK) Now

OPKO Health Inc. (NASDAQ: OPK) is 127.21% higher on its value in year-to-date trading and has touched a low of $1.12 and a high of $6.47 in the current 52-week trading range. The OPK stock was last observed hovering at around $3.31 in the last trading session, with the day’s gains setting it 0.03% off its average median price target of $7.75 for the next 12 months. It is also 66.6% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are 48.62% higher than the price target low of $6.50 for the same period.

Currently trading at $3.34, the stock is -32.50% and -24.55% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 17.68 million and changing 0.91% at the moment leaves the stock 37.03% off its SMA200. OPK registered 84.53% gain for a year compared to 6-month gain of 114.79%. The firm has a 50-day simple moving average (SMA 50) of $4.9551 and a 200-day simple moving average (SMA200) of $2.8432.

The stock witnessed a -43.49% loss in the last 1 month and extending the period to 3 months gives it a 38.02%, and is -31.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.78% over the week and 8.18% over the month.

OPKO Health Inc. (OPK) has around 6096 employees, a market worth around $2.22B and $965.80M in sales. Fwd P/E is 15.61. Profit margin for the company is -20.70%. Distance from 52-week low is 198.99% and -48.38% from its 52-week high. The company has generated returns on investments over the last 12 months (-14.90%).

OPKO Health Inc. (OPK) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for OPKO Health Inc. (OPK) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.80, where 1 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

OPKO Health Inc. is expected to release its quarterly report on 11/04/2020 and quarterly earnings per share for the current quarter are estimated at $0.04 with sales reaching $374.36M over the same period.The EPS is expected to shrink by -94.60% this year, but quarterly earnings will post 42.30% year-over-year. Quarterly sales are estimated to grow 63.60% in year-over-year returns.

OPKO Health Inc. (OPK) Top Institutional Holders

251 institutions hold shares in OPKO Health Inc. (OPK), with 266.95M shares held by insiders accounting for 39.85% while institutional investors hold 43.82% of the company’s shares. The shares outstanding are 640.58M, and float is at 403.12M with Short Float at 33.58%. Institutions hold 26.36% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 37.39 million shares valued at $127.49 million. The investor’s holdings represent 5.58% of the OPK Shares outstanding. As of Jun 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 37.22 million shares valued at $126.94 million to account for 5.56% of the shares outstanding. The other top investors are State Street Corporation which holds 30.46 million shares representing 4.55% and valued at over $103.86 million, while Oracle Investment Management Inc holds 1.80% of the shares totaling 12.05 million with a market value of $41.08 million.

OPKO Health Inc. (OPK) Insider Activity

A total of 135 insider transactions have happened at OPKO Health Inc. (OPK) in the last six months, with sales accounting for 0 and purchases happening 135 times. The most recent transaction is an insider purchase by Rubin Steven D, the company’s Executive VP-Administration. SEC filings show that Rubin Steven D bought 10,000 shares of the company’s common stock on Aug 26 at a price of $3.99 per share for a total of $39943.0. Following the purchase, the insider now owns 6.17 million shares.

OPKO Health Inc. disclosed in a document filed with the SEC on Jun 03 that FROST PHILLIP MD ET AL (CEO & Chairman) bought a total of 100,000 shares of the company’s common stock. The trade occurred on Jun 03 and was made at $2.27 per share for $0.23 million. Following the transaction, the insider now directly holds 190.22 million shares of the OPK stock.

Still, SEC filings show that on Jun 02, FROST PHILLIP MD ET AL (CEO & Chairman) acquired 100,000 shares at an average price of $2.42 for $0.24 million. The insider now directly holds 190,121,694 shares of OPKO Health Inc. (OPK).

OPKO Health Inc. (OPK): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 19.81% up over the past 12 months. Regeneron Pharmaceuticals Inc. (REGN) is 107.39% up on the 1-year trading charts. Short interest in the company’s stock has fallen -1.34% from the last report on Jul 14, 2020 to stand at a total of 137.17 million short shares sold with a short interest ratio of 5.88.